Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, ACC

Hansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business Update


LUND, Sweden, July 6, 2023 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-June 2023 at 8:00 CET on July 20, 2023. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, CCO and US President, Matthew Shaulis and CFO, Donato Spota. The presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Presentations" and will also be made available online after the call. Link to presentation

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 10 884 80 16

United Kingdom: +44 20 3936 2999

United States: +1 646 664 1960

Participant access code: 323180

The webcast will be available on https://events.q4inc.com/attendee/206699686

Financial calendar and events 2023

July 18, 2023            William Blair Conference Transitioning Biotech Breakthroughs to Commercial Success (virtual)

July 20, 2023            Half-year Report for January-June 2023

Aug 23, 2023            Carnegie non-deal road show, Stockholm

Aug 24, 2023            Erik Penser Company Day, Stockholm

Aug 30-31, 2023       Cowen US non-deal road show

Sept 6-7, 2023          CITI Annual BioPharma Conference, Boston

Sept 11, 2023           HC Wainwright Annual Global Investment Conference, NYC

Sept 11-12, 2023      MorganStanley Global Healthcare Conference, NYC

Sept 14, 2023           Pareto Annual Healthcare Conference, Stockholm

Sept 14, 2023           Erik Penser Company Day, Malmö

Oct 2, 2023              Redeye: Autoimmune and inflammatory disease, Stockholm

Oct 12, 2023            Redeye: Afterwork, Malmö

Oct 19, 2023            Interim Report for January-September 2023

Nov 21, 2023            SEB Healthcare Seminar 2023, Stockholm

Nov 22, 2023           Ökonomisk Ugebrev Life Science Event, Copenhagen

For further information, please contact:
Klaus Sindahl, VP Head of Investor Relations
M: +46 (0) 709?298 269
E: [email protected]

Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802
E: [email protected]

The following files are available for download:

https://mb.cision.com/Main/1219/3799653/2171310.pdf

20230703 HNSA - PR Conf call invite Q2 2023 ENG FINAL

 

SOURCE Hansa Biopharma AB


These press releases may also interest you

at 02:10
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance...

8 mai 2024
Tri-Tech Forensics, Inc. (Tri-Tech), a leading provider of tactical emergency medical solutions and human identification kits, is pleased to announce the acquisition of SAM® Medical (SAM Medical), a globally renowned provider of innovative medical...

8 mai 2024
The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria and neglected tropical diseases (NTDs).2  The...

8 mai 2024
Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced today that it has focused its development and commercialization efforts for its RT-100 and RT-200 gene...

8 mai 2024
Organovo Holdings, Inc. ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the...

8 mai 2024
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology...



News published on and distributed by: